Home Reproductive Health Tags

View the Latest: Reproductive Health

Filter

List Grid

111 - 120 of 515 Results

  • One Year Since Dobbs: The Landscape of Abortion Policies Across the US  

    News Release

    There has been intense focus on abortion policies across the United States since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization on June 24, 2022. That decision overturned Roe v. Wade, eliminating federal constitutional protections for abortion and putting the decision to restrict or protect abortion with the states.  Now, nearly one year later, what is the status of federal and state developments? Where is abortion banned? Where is litigation pending? And…

  • A Focus on Contraception in the Wake of Dobbs

    Perspective

    In this commentary for Women’s Health Issues, a publication of the Jacobs Institute of Women’s Health, KFF experts discuss contraceptive coverage and financing policies, access points within the delivery system, and the role of mis- and disinformation.

  • What Are the Exceptions to State Abortion Bans?

    News Release

    A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to state abortion bans generally fall into four general categories: to prevent the death of the pregnant person, when there is risk to the health of…

  • Update on the Status of Medication Abortion and the Courts

    Policy Watch

    This policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.

  • Medication Abortion in the Courts: What’s at Stake?

    News Release

    Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000, has a long record of safety and effectiveness and has been used by more than 5 million people in the United States. In the most…

  • Many Women Use Preventive Services, but Gaps in Awareness of Insurance Coverage Requirements Persist: Findings from the 2022 KFF Women’s Health Survey

    Issue Brief

    This brief presents findings from the 2022 KFF Women’s Health Survey on women’s receipt of cancer screenings and other preventive services and differences between subgroups of women. We also present data on women’s and men’s awareness of federal requirements for private insurance coverage of preventive services.

  • The Public, Including Women of Childbearing Age, Are Largely Confused About the Legality of Medication Abortion and Emergency Contraceptives in Their States

    News Release

    More than six months since the Supreme Court issued their Dobbs decision which overturned Roe v. Wade, there is widespread public confusion about the medication abortion pill and whether it is legal at the state level, according to the latest KFF Health Tracking Poll. The poll also finds many are unsure about the legality of emergency contraceptive pills, sometimes called morning after pills or “Plan B,” and whether the pills can end a pregnancy. Across…